Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. ResMed (NYSE:RMD) is seeing growing use of wearable devices for sleep apnea pre ...

Sydney: Sleep-breathing device maker ResMed plans to take global a doctor ‍education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for apnea, ⁠calling ...

Resmed posts double-digit revenue and profit growth in Q2 FY26, declares dividend, and outlines plans for innovation. The Resmed CDI (ASX: RMD) share price is in focus after the company reported ...

Jan 29 (Reuters) - Medical device maker ResMed (RMD.N), opens new tab on Thursday beat Wall Street estimates for second-quarter profit on the back of strong demand for its devices used to manage sleep ...

ResMed (RMD) came out with quarterly earnings of $2.81 per share, beating the Zacks Consensus Estimate of $2.69 per share. This compares to earnings of $2.43 per share a year ago. These figures are ...

ResMed (NYSE:RMD) is set to give its latest quarterly earnings report on Thursday, 2026-01-29. Here's what investors need to know before the announcement. Analysts estimate that ResMed will report an ...

Resmed believes its artificial intelligence-powered approach to personalizing the settings of its connected CPAP machines can lead to better sleep for people with obstructive apnea. Now the FDA has ...

ResMed is rated a buy due to strong fundamentals, expanding margins, robust cash flow, and resilience in recessionary environments. RMD's steady topline growth, high profitability, low debt, and ...

Fractus, a company specializing in geometry-based antenna technology and IP licensing, has filed a patent infringement suit against respiratory leader ResMed. The complaint was filed in the United ...

ResMed plans to sign a lease for an about 446,500-square-foot building on Collins Road in Greenwood. The company is seeking a nearly $500,000 three-year tax break from the Greenwood City Council.